Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is expected to post its Q1 2026 results after the market closes on Thursday, May 14th. Analysts expect Spyre Therapeutics to post earnings of ($0.66) per share and revenue of $70.8710 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:00 AM ET.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.08). On average, analysts expect Spyre Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Spyre Therapeutics Stock Up 1.9%

Spyre Therapeutics stock opened at $76.43 on Tuesday. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of -36.75 and a beta of 3.12. The business has a 50-day simple moving average of $54.76 and a 200 day simple moving average of $39.40. Spyre Therapeutics has a 52 week low of $13.93 and a 52 week high of $78.80.

Analysts Set New Price Targets

SYRE has been the topic of several research reports. JonesTrading raised their price objective on shares of Spyre Therapeutics from $64.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, April 17th. Raymond James Financial initiated coverage on Spyre Therapeutics in a research note on Monday, April 13th. They issued a “strong-buy” rating and a $80.00 target price on the stock. BTIG Research raised their price target on Spyre Therapeutics from $70.00 to $98.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Jefferies Financial Group upped their price objective on Spyre Therapeutics from $47.00 to $85.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Finally, Citigroup upped their price objective on Spyre Therapeutics from $64.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $89.08.

Insiders Place Their Bets

In related news, insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price of $71.50, for a total value of $5,600,809.50. Following the sale, the insider owned 78,333 shares in the company, valued at $5,600,809.50. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $71.37, for a total value of $892,125.00. Following the completion of the transaction, the chief financial officer owned 97,994 shares of the company’s stock, valued at approximately $6,993,831.78. The trade was a 11.31% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 233,791 shares of company stock valued at $15,757,860 over the last three months. 15.69% of the stock is currently owned by corporate insiders.

Institutional Trading of Spyre Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Spyre Therapeutics by 18.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company’s stock worth $442,000 after acquiring an additional 4,277 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Spyre Therapeutics by 13.8% during the second quarter. JPMorgan Chase & Co. now owns 47,279 shares of the company’s stock valued at $708,000 after acquiring an additional 5,723 shares in the last quarter. Rhumbline Advisers raised its position in shares of Spyre Therapeutics by 30.6% in the 2nd quarter. Rhumbline Advisers now owns 73,168 shares of the company’s stock worth $1,095,000 after purchasing an additional 17,145 shares during the last quarter. New York State Common Retirement Fund boosted its stake in Spyre Therapeutics by 61.4% in the 2nd quarter. New York State Common Retirement Fund now owns 16,565 shares of the company’s stock worth $248,000 after purchasing an additional 6,300 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Spyre Therapeutics by 37.6% in the 2nd quarter. Invesco Ltd. now owns 34,680 shares of the company’s stock worth $519,000 after purchasing an additional 9,473 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.